Executive readout · one minute
Webcast research workspace
Read the call alongside every captured source. Transcript, audio stay in one workspace.
Substantial doubt about the company's ability to continue as a going concern.
“If we are unable to raise additional capital when needed, that could raise substantial doubt about our ability to continue as a going concern.”View the 10-Q filed Nov 4, 2026
Conference · 2026-11-09
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Executive readout · one minute
Read the call alongside every captured source. Transcript, audio stay in one workspace.
Research coverage
2 live sources
Switch sources without leaving this page or losing your listening position.
Open the source you need; every reader stays inside this workspace.
All right. Good afternoon, everyone. Welcome to the last session of the day at our first day of the Guggenheim Healthcare Innovation Conference. My name is Rosie Lau, member of the biotech research team here at Guggenheim Securities. With me, I have the team at DeMora Therapeutics, Becker Hughes, Chief Medical Officer, and Cheryl Wrens at Harzadeh, Chief Operating Officer. Great to have you here with me. So for those in the audience who are maybe less familiar with the story, could you just start with a quick overview of the company and maybe give a high-level view of where you guys are at today across the pipeline?
Sure. Thanks, Rosie, for having us here today. Hi, everyone. Before I get started, we're going to be making some forward-looking statements, so refer everyone to our latest SEC filings for risk factors and other information. My name is Sherwin Sitarzadeh. I'm the Chief Operating Officer at DeMora, Becker-Hughes, Chief Medical Officer. We worked together at Blueprint Medicines before this, working on bringing an important medicine to the market and the hematology space. DeMora is in the MPN space. We are advancing a portfolio of potential best-in-class antibodies for the treatment of essential thrombocythemia and myelofibrosis, both of which are severely debilitating diseases. I think many people know about myelofibrosis. Which causes the bone marrow fibrosis leading to reduced overall survival, and ET is a very serious disease that comes with the risk of thrombosis and hemorrhage and the risk of progression to myelofibrosis. DMR-001 is our lead asset. It is an FC null antibody that is a pan-butin inhibitor with a long-lasting half-life that compares favorably against the lead competitor molecule in the space at the moment that has significantly de-risked the biology, and we are looking to advance our program forward in those two indications. MPNs are a very large market opportunity with over a $5 billion U.S. opportunity alone. We'll talk a little bit about the prevalence of the different mutant CalR mutations, but this is about a 45,000 patient population in the U.S. that currently does not have any disease-modifying therapies, and really the therapies right now are just symptomatic improvement agents. We've recently started our phase one study. It's called Clarity 101. It'll be a global study. It's in the U.S. and Australia already, and we'll be rolling out more broadly beyond that, and we're looking to very rapidly move this DMR-001 through dose escalation and into expansion to bring it to patients with both type 1 and non-type 1 patients that are waiting for this therapy. Lastly, I'll just say we have $530 million in cash and have built a team of highly experienced hematology, oncology, drug developers, and we'll be moving the program quickly towards phase three, which we anticipate starting in mid-2028.
Great. That was a great opener. Maybe I'll just kind of double-click on the mutant color opportunity, which you kind of alluded to already. Obviously, the space has become one of the more exciting targets in MPNs over the past year. I guess you kind of talked about this, but how do you think about the size and the shape of the opportunity across both ETE and MF, and where do you see the greatest unmet need?
Myelofibrosis therapies have been around for some time, about 10, 15 years now, and generate billions of dollars worldwide. These are primarily JAK-directed therapies, and there have not been disease-modifying therapies for mutant CalR patients. After JAK, mutant CalR makes up the next largest group of patients with about 25% of ET patients having a CalR mutation, And about 35% of ET patients, amounting to about 45,000 patients worldwide. The current therapy, our lead competitor of Insight 989, has really de-risked the biology in the space and has demonstrated that a FC-null targeting agent in looking at mutant CalR is a viable path to treating these patients. Unfortunately, the activity of that agent right now is really in the type 1 patients and less so in the non-type 1 patients, as well as its limitations on its PK profile, its high dose, and frequent volume of route of administration. And so we're looking to bring forward DMR001 with an every-four-week sub-Q administration, pan-mutant activity, as we've recently talked about, and we'll be talking about more as ASH data is presented for the broader patient population.
Great, and that's a good segue into my next question, which is kind of diving a little bit deeper on DMR001. So you'll present new preclinical data at ASH on activity across the different mutant types. I guess, what should we take away from that data set?
Yeah, I think what's been shown thus far is that the targeting of mutant CalR with the inside molecule has clearly demonstrated that you can gain good activity for both ET and MF patients. And yet there's about 50% of the population who have the non-type 1 mutations that really are not seeing the same level of benefit as what DMR-001 can bring. What we've also done is improved the PK profile relative to what they've been able to show to have a much longer-lasting antibody that can be dosed far less frequently than 989 can.
I guess, kind of speaking to that longer half-life, I guess, how confident are you that what you've seen in preclinical studies will translate into humans, and what do you really need to see to kind of confirm that in the clinic?
Yeah, I mean, I think the preclinical data that 989 demonstrated is really playing out in the clinic as was originally expected. And so their shorter half-life, their potency primarily on the type 1 molecule, really gives us confidence that our preclinical profile will be able to address those limitations as we move it forward. You know, what we want to see is... You know, particularly in the early part of the study is to see that translation of our PK profile, of our preclinical profile into the clinic. And so we'll be looking at that activity across mutations. We'll be looking for that validation of the PK half-life in humans to really lend proof to the differentiation of this molecule.
Great. So we dive into your trial, Clarity 101. This trial is currently enrolling. You're planning for this to be a global trial, from what I understand. Can you just remind us where you are in terms of site activations and also with the global regulatory clearance? Can you also maybe just walk us through the design and, I guess, how quickly do you expect to reach a recommended dose for expansion?
Yeah, I can start.
Sorry, it's a very loaded question.
That's it to Becker. Yeah, so as we disclosed last week, the IND has been cleared by the FDA. The study is ongoing in the U.S. and in Australia. We are planning for this study to be a global, large study. It's likely going to be the largest MPN study that's been conducted in phase one thus far. So we've got 250 patients in the study that the protocol allows. And we have a very interesting study design, a Bayesian escalation design that I'll let Becker speak to.
Yeah, so the study is designed to answer a lot of different questions and to really set us up to be able to start our pivotal studies as quickly as possible. And this would be both for MF and for ET, and we will explore both single agent and, if necessary, combination with ruxolitinib. The significance of the Bayesian design is that it allows us to continue to explore doses as we expand in different parts of the disease. So imagine we have good evidence of efficacy and safety in ET, and we're still trying to understand the activity in myelofibrosis. Myelofibrosis takes a little bit longer to read out because you have to wait for a spleen scan and symptoms to resolve. We can go full bore into the expansion of the ET population as we continue to look at the myelofibrosis population. So that was an important thing to make sure that we kept speed going. And then our starting dose, 100 milligrams, is within the therapeutic range. And we don't expect this to be an extensive dose escalation. We expect to have to go through a few doses to better understand where the activity lies. But we really expect the escalation portion to just be setting up that expansion portion.
Great. And I believe you're also perhaps thinking about including patients who have previously seen a KELR antibody. Can you just walk us through kind of the rationale behind that process?
So we've set up this trial to allow a very broad patient population, and that includes ET, NMF, and even pre-fibrotic MF patients. This is to make sure that enrollment goes quickly and we get a full view of the efficacy across the spectrum of the indication. With respect to patients that have been on other agents before, as we said, the preclinical data should tell us what will happen in the clinic. And so we've got patients who may have been on 989 or may have been on the J&J T-cell engager, And we believe that DMR001 will maintain or will have activity even where those agents do not have activity. So with respect to 989, even in type 1, if you can imagine a patient with myelofibrosis, they've got marrow with a lot of fibrosis in there. And having the intermittent therapy that 989 brings may not either get them as deep a response as they can have or maintain that response for a long period of time. And then certainly for patients with a type 2 mutation, we believe that the preclinical data indicates a much higher level of activity for DMR001, and so it would be logical to be able to put those patients that had been on 989 onto DMR001. And then the T-cell engagers, I think the response rate that we saw in the ET population with the J&J agent wasn't quite as deep as we expected it to be, and there is room for improvement upon that, and we think DMR001 can bring that to bear.
Great. So you've guided to two clinical proof of concept readouts beginning in mid-2027. I guess as we head into that catalyst, there's been a lot of discussion just about endpoints recently, especially with Insight starting their phase three trials. I guess what are your thoughts on kind of which endpoints will matter the most and your thoughts on maybe the composite endpoints? And how much weight will you put on kind of molecular markers such as allele burden?
I would start with, maybe we'll start with ET for a second. Really watching how INSIGHT has developed the primary endpoint for that study, or primary and secondary endpoints for that study, we're really happy with that. You know, having gotten to a place with the FDA where they can introduce, you know, VATH as a key secondary endpoint with obviously complete hematologic response as a primary endpoint, agreeing on a 24-week duration for that endpoint, you know, that's a really great outcome, and we'll probably be looking at, you know, mirroring something like that in the ET side of it. On the myelofibrosis side, you know, again, very much happy to have them in conversations with the FDA about evolving beyond SVR and TSS50 and trying to get things like VAF or transfusion independence into endpoints for myelofibrosis. Of course, we know for second-line study, they've landed on SVR and TSS. Interestingly, they need to account for the type 1, non-type 1 activity, and so prioritizing the type 1 analysis there. But again, allowing for some continued dialogue that they're going to have in the frontline setting, we'll see what their ASH data, as they've alluded to, a little bit more mature later data cut coming out at ASH to see what that frontline data looks like and how the activity between type 1 and non-type 1 fares in that earlier line setting, as well as potentially looking at combination versus monotherapy and how those factor into a phase 3 study design. And so, you know, we'll see how this continues to evolve, but nice to see that they're landing in a place where they can potentially demonstrate, you know, benefit with those study designs, as well as just the creativity of going with a 36-week endpoint instead of 24 weeks, allowing for the mutant CalR TSS to mature over time.
Great. And maybe turning to your own data set that you'll have next year, I guess, what do you think of as kind of the benchmark or the bar that you need to show for your readouts? And there's been some discussion recently just on, you know, how that, you know, M-CALR patients might do maybe a little bit worse on the traditional endpoints compared to what we've seen for Jacofi and the comfort studies. Does that align with how you're thinking about it as well?
Yeah. So, you know, as we look into data disclosures next year, with the study progressing through dose escalation, we're really going to be looking for the translation of that preclinical profile into the clinic, looking for the, you know, pan mutant activity, as well as some of the early signals that we can expect for the translation of the PK profile into human half-life. If you think about the maturation of the data sets and the time points at which disease assessments are done between ET and MF, you can think, you know, perhaps some earlier data set will be, you know, more indicative, more reflective of those earlier disease readouts. And then, what was the second part of your question?
Oh, just on the MCAL, our patients may be doing a little bit worse.
Yeah, I mean, I think Insight, you know, certainly has alluded to that several times. If you look at their EU label for Jackify, it certainly speaks to the SVR rate being lower in the non-Jack2 mutated patients. So, again, that just helps understand the type of phase three study you're going to have to run and the size of that study as you try to demonstrate, you know, much better SVR rates in the CalR patients. You know, as we're starting to see with the type one patients that 989 has demonstrated in both front line and second line, it's the non-type one patients that we're looking to show, you know, significantly better improvement on their, Great.
I guess as we're talking about kind of your development plans here, I guess, could you maybe just walk us through kind of what your general strategy is and how you're prioritizing the different indications? And I guess, you know, I think you've also mentioned that potentially lower risk patients could also be a meaningful opportunity for you. Can you just maybe walk us through kind of your thought process there?
Yeah. In the phase one study, we're not prioritizing one population over the other. Both ET and MF patients are going to be part of the dose escalation, and then we will have population-specific expansions from there. So certainly not looking to prioritize one population over the other. I think, again, as you see the maturation of the data, ET, you know, platelet counts are sort of an earlier readout than the endpoints you have in myelofibrosis. But, again, our anticipation, our expectation is to take OO1 forward in both populations. And, you know, in terms of which lines of therapy we take them forward in, it's going to depend on the data and how that matures.
Great. And then, I guess, going back to the lower risk population, is that something that you're interested in developing in?
Yeah, I mean the way we kind of think about it is The FCNL approach, FCNL mutant CalR antibody, it should be the backbone of, you know, lifelong treatment for these patients. And so when we look at a patient who is early line versus post-prior therapies, there's really no reason to think that you wouldn't want to treat that patient with a targeted, you know, anti-mutant CalR agent. And when we speak with our physicians and KOLs, there's clearly an interest in driving the use of these agents earlier and earlier in the course of the disease, rather than waiting until patients are a little bit more advanced. So absolutely, we'll be looking at those earlier patients.
Great. We've been talking about just 99s data a lot. I guess they're expecting more data at ASH. I guess, as we kind of see more data from that program, what questions do you think they're answering for the class versus what do you think that you will need to answer for yourself?
Yeah, I think, you know, certainly they've demonstrated the type 1 activity on the ET. We need to demonstrate the activity on the remaining patient population, which is about half the population. So we're certainly going to be looking to answer that question. I think an outstanding question on the myelofibrosis side of things still continues to be monotherapy versus combination. What is the additive effect of combining an anti-mutant CalR agent with a JAK inhibitor? I think we can also think, you know, perhaps beyond ruxolitinib, and are there other JAK inhibitors that would make sense for us to study in combination? And then really to see sort of how that with the type 1, non-type 1 kind of come together to understand what the registration study for registration program for 001 could look like.
Great. Makes sense. So earlier we talked about kind of the overall size of the market. I guess, how do you think of DMR001's opportunity in a market where we could potentially have multiple options approved?
Yeah, that's a good question. So, again, I think when we look at the different sort of modalities that are available here, the FCNOL, you know, effective and safe sort of modality should become the backbone of lifelong therapy for patients with these diseases. When we look at sort of what other constructs there may be, we look at J&J's TCE data that recently came out, as Becker was saying, you get some of the safety effects as expected with the TCE, but you're not really seeing the upside on the efficacy side of things. And so what that does sort of for our portfolio is we also have DMR002, and we can look at the sort of bringing in a little bit more of the immune activation rather than just the signal blockade you get with the FCNAL approach, as well as the signaling blockade that you don't get with the TCE approach. So, 002 kind of gives us another tool in the arsenal of treatment for these patients. As we look beyond our portfolio and, you know, what's coming behind us, we really don't see a data set that's meaningfully differentiated from what 001's already bringing. The step change from 989 to 001, we talk about the non-type 1 activity, we talk about PK, the convenience, the volume of administration, route of administration, and then we look at what's coming behind in the next set of compounds, and you don't see that same differential improvement over what O01 is bringing. So really like where we're positioned right now with our portfolio.
Great. And you mentioned O02. We also have O03. So can you maybe just walk us through kind of the rationale behind pursuing you and CalR from these three different angles? And I guess like maybe just elaborate a little bit more on kind of where you really see kind of, you know, All three of them fitting, whether the FC Null, FC Enhance, or the Bi-Specific.
Yep. So DMR-001 is our lead program. We will be prosecuting that across the different patient populations we've been talking about. The great advantage we have is that DMR-002, we're going to file that application to regulators this quarter, and that'll be in the clinic in the first half of next year. So we'll have 001 and 002 in the clinic at the same time, and can really start to understand what a more potent FC null antibodies can do for the broad spectrum of patients, and then where is there still a need for, you know, perhaps more severe patients, and where an FC enhanced antibody can work, or if you need a TCE as well. I think the data that we saw from ET, from the J&J TCE and ET, leaves some questions still. We haven't seen the myelofibrosis data set yet. So as the data matures, we have the option to build a TCE that kind of addresses whatever limitations that the other TCEs currently have.
As you mentioned, perhaps, you know, reserving the 002, the FC-enhanced molecule for more severe patients. Is that something that you think will be limited to severe patients, or could that potentially be applicable to a broader population over time?
I think time will tell. Again, the advantage of having both in the clinic is going to be that as the data matures from or data emerges from one, informs the development of the other, and vice versa. And so, you know, I don't think at the moment we need to define exactly where it's going to play. What we do know is that given the safety profile we're seeing with the FCNAL approach, given the anticipated pan-mutant activity we want with 001, it sort of becomes the mainstay of treatment for patients for the long term, and then we'll see where 002 and 003 are needed.
Great. So you mentioned at the beginning your cash balance. How are you thinking about prioritizing investment across the pipeline as each kind of move forward?
Yeah, so we're in the fortunate position of having about $530 million in cash. We are rapidly scaling the organization to prosecute against our ambitious goals. You know, the way that that shows up currently is that we don't have to gate certain investments. We can move things quickly. We're already thinking about what our phase three studies could look like. We're accelerating our activities to develop an auto-injector to have that ready to go as early as possible and moving multiple programs forward in parallel. So we don't really need to prioritize today against those things. OO1 is going to go as fast as possible. OO2 will be in the clinic. And then as these data emerge, we'll understand exactly where we're going to play with each other.
Great. And then longer term, is business development something you would consider, whether bringing in new assets or maybe partnering out some of your own programs?
Yeah, I think, you know, with our background in hematology drug development, with the team that we're building, we certainly want to look beyond mutant CalR in terms of what our portfolio is going to look like. So we engage with others. We are searching for assets that could round out our portfolio on the heme side as well, sorry, on the NPN side, and then more broadly on heme as the organization matures.
Great. I think that's all we had for today. Becker and Sherman, thank you so much for joining us again.